For the quarter ending 2025-09-30, DNTH had $42,683K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -36,765 | -61,140 |
| Depreciation expense | 27 | 57 |
| Stock-based compensation expense | 5,794 | 11,021 |
| Accretion of discount on investment securities | 2,311 | 2,997 |
| Amortization of right-of-use operating lease assets | 72 | 175 |
| Gain on investment in former related party | 227 | 27 |
| Receivable from former related party | 0 | -807 |
| Unbilled receivable from former related party | 0 | 0 |
| Accounts receivable, net | 4,961 | 39 |
| Prepaid expenses and other current assets | 35 | 1,321 |
| Other assets | -89 | -476 |
| Accounts payable, accrued expenses and operating lease liabilities | 3,004 | 1,589 |
| Deferred revenue | 4,758 | -123 |
| Deferred revenue - former related party | 0 | 0 |
| Net cash used in operating activities | -30,555 | -51,522 |
| Capital expenditures | 5 | 70 |
| Purchases of investment securities | 279,841 | 100,437 |
| Proceeds from maturities of investment securities | 78,571 | 141,746 |
| Net cash used in investing activities | -201,275 | 41,239 |
| Proceeds from public offering | 272,268 | - |
| Payment of issuance costs in connection with public offering | 172 | - |
| Proceeds from exercise of stock options | 2,230 | 599 |
| Proceeds from issuance of common stock under espp | 187 | 129 |
| Proceeds from exercise of pre-funded warrants | 0 | 1 |
| Proceeds from private placement | 0 | 0 |
| Payment of issuance costs in connection with private placement | 0 | 0 |
| Net cash provided by financing activities | 274,513 | 729 |
| Increase/(decrease) in cash, cash equivalents and restricted cash | 42,683 | -9,554 |
| Cash and cash equivalents at beginning of period | 23,022 | - |
| Cash and cash equivalents at end of period | 56,151 | - |
Dianthus Therapeutics, Inc. DE (DNTH)
Dianthus Therapeutics, Inc. DE (DNTH)